Paper Details

  1. Home
  2. Paper Details

Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes.

Author: AlicandroGianfranco, BlasiFrancesco, DaccòValeria, GramegnaAndrea, GranciniValeria, LanfranchiChiara, OrsiEmanuela, PiedepalumboFederica, PorcaroLaura L, ZazzeronLaura

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluated the effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI), a triple combination therapy for cystic fibrosis (CF), on glucose metabolism, glucose variability, and body composition in CF patients with CF-related diabetes requiring insulin therapy. After six months of treatment, HbA1c and glucose variability decreased significantly, despite unchanged insulin requirements.
Paper Details　
Original Abstract of the Article :
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are a group of new drugs for the treatment of cystic fibrosis (CF) and elexacaftor + tezacaftor + ivacaftor (ETI) triple combination therapy has been approved as first choice therapy in the treatment of patients with at least 1 co...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.diabet.2023.101466

データ提供：米国国立医学図書館（NLM）

CFTR Modulators: A New Era in Cystic Fibrosis Treatment

Cystic fibrosis (CF) is a genetic disorder that affects the lungs and other organs. This study explores the effects of elexacaftor + tezacaftor + ivacaftor (ETI), a triple combination therapy for CF, on glycaemic control and body composition in patients with CF-related diabetes. The authors observed a significant decrease in HbA1c and glucose variability despite unchanged insulin requirements after six months of treatment. However, they also noted an increase in fat mass, highlighting the need for continued monitoring and adjustments to treatment strategies.

A Promising Treatment Option for CF-Related Diabetes

The study provides evidence that ETI therapy can improve glycaemic control in patients with CF-related diabetes, offering a potentially valuable treatment option for this complex condition. However, the research also highlights the need for careful monitoring of body composition to address the potential for weight gain and metabolic changes associated with this therapy.

Optimizing Treatment for CF: A Journey of Adaptation

The study underscores the importance of personalized care and ongoing monitoring in managing CF and CF-related diabetes. As we navigate the complexities of this disease, we must continue to develop and refine treatment strategies to ensure the best possible outcomes for patients. Just as a camel adapts to the changing conditions of the desert, we must adapt our approach to CF treatment to meet the individual needs of each patient.

Dr.Camel's Conclusion

This study offers insights into the effects of ETI therapy on glycaemic control and body composition in patients with CF-related diabetes. While the therapy shows promise in improving glycaemic control, careful monitoring of body composition is crucial to address the potential for weight gain. Just as a camel navigates the desert, seeking out nourishment and adapting to the environment, we must find the optimal balance in treating CF, ensuring both effective management and a healthy lifestyle for patients.

Date :
  1. Date Completed 2023-10-02
  2. Date Revised 2023-11-21
Further Info :

Pubmed ID

37536552

DOI: Digital Object Identifier

10.1016/j.diabet.2023.101466

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.